Results 41 to 50 of about 2,423,192 (204)

Balloon pulmonary angioplasty: a treatment option for inoperable patients with chronic thromboembolic pulmonary hypertension

Frontiers in Cardiovascular Medicine, 2015
In chronic thromboembolic pulmonary hypertension, stenoses or obstructions of the pulmonary arteries due to organized thrombi can cause an elevation in pulmonary artery resistance, which in turn can result in pulmonary hypertension.
Aiko eOgawa, Hiromi eMatsubara
doaj   +1 more source

Real‐World Safety and Effectiveness of JAK Inhibitors in Systemic Sclerosis: A Propensity‐Matched Study From the EUSTAR Cohort

Arthritis Care &Research, EarlyView.
Objective JAK inhibitors (JAKi) have shown promising effects in early‐phase studies of systemic sclerosis (SSc). We aimed to assess the safety and explore the effectiveness of JAKi compared to conventional immunosuppressants in SSc. Methods A longitudinal retrospective study of the European Scleroderma Trials and Research Group (EUSTAR) cohort was ...
Stefano Di Donato, Marie‐Elise Truchetet, Marco Minerba, Oliver Distler, Juan José Alegre Sancho, Yolanda Braun‐Moscovici, Christina Bergmann, Petros Sfikakis, Jeska K. de Vries‐Bouwstra, Murray Baron, Silvia Bellando‐Randone, Lorenzo Dagna, Christopher P. Denton, Madelon C. Vonk, Vanessa Smith, Ivan Castellvi, Gabriela Riemekasten, Andra Balanescu, Masataka Kuwana, Maria De Santis, Kamal Solanki, Anastas Batalov, Vahan Mukuchyan, Marco Matucci‐Cerinic, Yannick Allanore, Francesco Del Galdo, Michael Hughes, EUSTAR Collaborators   +27 more
wiley   +1 more source

Tadalafil in patients with chronic obstructive pulmonary disease:a randomised, double-blind, parallel-group, placebo-controlled trial [PDF]

, 2014
Background: Phosphodiesterase-5 (PDE5) inhibitors improve exercise capacity and quality of life in patients with idiopathic pulmonary arterial hypertension.
Lipworth, Brian J., Hopkinson, Pippa J, Struthers, Allan D., Goudie, Andrew R, Hopkinson, Pippa J., Lipworth, Brian J, Goudie, Andrew R., Wei, Li, Struthers, Allan D   +8 more
core   +1 more source

Chronic Thromboembolic Pulmonary Hypertension and Chronic ThromboembolicPulmonary Disease (CTEPD): Clinical and Interventional Perspective

, 2022
After an episode of acute pulmonary embolism chronic thrombotic lesions may persist at the level of the pulmonary circulation causing different clinical scenarios, from asymptomatic patients with complete functional recovery to chronic thromboembolic ...
Galie N., Palazzini M., Guarino D., Manes A., Dardi F., Saia F., Taglieri N.   +6 more
core   +1 more source

Targeting B‐Cell‐Activating Factor and Its Receptor in Immune Thrombocytopenia and Warm Autoimmune Hemolytic Anemia

American Journal of Hematology, EarlyView.
ABSTRACT Current treatments for immune thrombocytopenia (ITP) and warm autoimmune hemolytic anemia (wAIHA), rare autoimmune diseases in which autoreactive B cells play a major role, can lead to high response rates; however, for many patients these responses are not durable or maintained after treatment discontinuation.
Matthieu Mahévas, Nichola Cooper, Vickie McDonald, Karina Yazdanbakhsh, Wilma Barcellini   +4 more
wiley   +1 more source

Pulmonary vascular imaging characteristics after pulmonary endarterectomy for chronic thromboembolic pulmonary hypertension

, 2020
BACKGROUND: Between 16% and 51% of patients with chronic thromboembolic pulmonary hypertension will have residual pulmonary hypertension (PH) after pulmonary endarterectomy (PEA).
de Man, Frances S., Symersky, Petr, Bogaard, Harm Jan, Marcus, J. Tim, Lely, Rutger J., Klok, Frederikus A., Schokker, Monique G.M., Beijk, Marcel A.M., Braams, Natalia J., Schokker, Monique G. M., Vonk Noordegraaf, Anton, Nossent, Esther J., Ruigrok, Dieuwertje, Meijboom, Lilian J., Huisman, Menno V., Beijk, Marcel A. M., Padervinskiene, Lina   +16 more
core   +1 more source

Clinical–radiological–pathological correlation in chronic thromboembolic pulmonary hypertension

European Respiratory Review, 2023
Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare and potentially life-threatening complication of acute pulmonary embolism. It is characterised by persistent fibro-thrombotic pulmonary vascular obstructions and elevated pulmonary artery ...
Tom Verbelen, Laurent Godinas, Peter Dorfmüller, Deepa Gopalan, Robin Condliffe, Marion Delcroix   +5 more
doaj   +1 more source

Safety and pharmacokinetics of mosliciguat, a new, inhaled soluble guanylate cyclase activator, in healthy adult subjects

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Mosliciguat (BAY 1237592), the first soluble guanylate cyclase (sGC) activator in a dry powder inhaler (DPI), could potentially treat pulmonary hypertension with a more targeted delivery than systemic sGC stimulators. We report safety and tolerability of mosliciguat in healthy men.
Johannes Nagelschmitz, Soundos Saleh, Sandra Ligges, Melanie Seidel‐Greven, Eva Becker‐Pelster, Sylvia M. Nikkho, Stefanie Boxnick, Wolfgang Timmer   +7 more
wiley   +1 more source

Highlights from the International Chronic Thromboembolic Pulmonary Hypertension Congress 2021 [PDF]

, 2023
Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare complication of acute pulmonary embolism. It is caused by persistent obstruction of pulmonary arteries by chronic organised fibrotic clots, despite adequate anticoagulation.
Madani, M.M., Kim, N.H., Madani, Michael, Lang, Irene M., McInnis, Micheal C., Simonneau, Gerald, Ghofrani, H.A., Klok, Frederikus A., Kim, Nick, Guth, Stefan, Jenkins, David P, Jenkins, David, Hoeper, Marius M., Lang, Irene, Simonneau, G. rald, Matsubara, Hiromi, Fadel, E., Jaïs, Xavier, Kim, Nick H., Wiedenroth, Christoph, Brénot, P., Simonneau, G., Ghofrani, Hossein, Salaunkey, K., Pepke-Zaba, Joanna, Noordegraaf, Anton Vonk, Delcroix, M., Matsubara, H., Screaton, Nicholas, Wiedenroth, Christoph B., Klok, Frederikus A, Klok, Frederikus, Noordegraaf, A.V., Hoeper, Marius M, Klok, F.A., Brénot, Philippe, Kim, Nick H, Mayer, E., Martinez, Guillermo, Wiedenroth, Christoph B, Hoeper, Marius, Mcinnis, Micheal, Madani, Michael M., Pepke-Zaba, J., Mayer, Eckhard, Jenkins, David P., Lang, I.M., Salaunkey, Kiran, Vonk Noordegraaf, Anton, Toshner, Mark, McInnis, Micheal C, Wiedenroth, C.B., Hoeper, M.M., Jaïs, X., Toshner, M., Guth, S., Ghofrani, Hossein A., Screaton, N., Madani, Michael M, Fadel, Elie, McInnis, M.C., Martinez, G., Ghofrani, Hossein A, Delcroix, Marion, Jenkins, D.P., Lang, Irene M   +65 more
core   +1 more source

CYP3A5 genetic variability influences sildenafil and metabolite in pulmonary hypertension

British Journal of Clinical Pharmacology, EarlyView.
Aim Interindividual variability in sildenafil response among pulmonary hypertension patients (PH) may be influenced by CYP3A5 polymorphisms. CYP3A5*3 allele reduces CYP3A5 activity and affects sildenafil metabolism. This study investigated the associations between CYP3A5 genotype and plasma concentrations of sildenafil and N‐desmethyl sildenafil, as ...
Pranisa Wongwien, Burabha Pussadhamma, Sirimas Kanjanawart, Thikhumporn Areesinpitak, Nontaya Nakkam, Chingching Foocharoen, Wichittra Tassaneeyakul, Suda Vannaprasaht   +7 more
wiley   +1 more source